Galeterone safe and effective against prostate cancer

Bookmark and Share
Published: 13 Apr 2012
Views: 16776
Dr Bruce Montgomery - University of Washington, Seattle, USA

Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading the androgen receptor protein.


Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012.


ecancerNews Coverage: Early clinical data show galeterone safe, effective against prostate cancer